This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK, March 19, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company will present at three sessions at the Alliance for Regenerative Medicine (ARM) 2nd Annual Regen Med Investor Day, to be held on March 26, 2014. Additionally, Dr. Robin Smith, Chairman and CEO of NeoStem, will be presenting at BioCentury's 21
Future Leaders in the Biotech Industry conference, to be held on March 28, 2014. Both conferences will take place in New York City.
ARM's Regen Med Investor Day is a full-day conference combining discussions between key opinion leaders, top analysts and senior executives with an afternoon of presentations by the industry's most promising companies. Executives from NeoStem, and its wholly-owned subsidiary Progenitor Cell Therapy (PCT), will be speaking at the event alongside other notable feature speakers from leading companies in the industry, including Silviu Itescu, CEO, Mesoblast; Perry Karsen, CEO, Celgene Cellular Therapeutics, and COO & EVP, Celgene Corporation; and Eric Roman, GM, Research & Applied Markets, GE Healthcare Life Sciences.
Future Leaders conference brings together the corporate and investment communities and features presentations by both private and public biotechnology companies. Last year's event included more than 500 delegates representing top financial institutions, pharmaceutical business development executives, and high net worth investors active in the sector.
Alliance for Regenerative Medicine (ARM) 2nd Annual Regen Med Investor Day
Date: Wednesday, March 26, 2014
Venue: Metropolitan Club, One East 60th Street, New York, NY
Speaker: Dr. Robin L Smith, Chairman and CEO, NeoStem
Topic: NeoStem Company Presentation
About NeoStem, Inc.
NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
Progenitor Cell Therapy (PCT), a wholly owned subsidiary of NeoStem, Inc., is a leading contract development and manufacturing organization in the cellular therapy industry. For more than 15 years, PCT has provided pre-clinical and clinical cGMP development and manufacturing services to 100+ clients, advancing regenerative medicine product candidates from the development stage all the way through to human testing. PCT has two cGMP-compliant, state-of-the art facilities in New Jersey and California and offers manufacturing of cell therapy-based products; engineering and innovation services; process and product development; cell and tissue processing; collection and storage; regulatory consulting; facility design, validation, and due diligence evaluations.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's ability to develop and grow its business, the successful development of cellular therapies, including with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's CD34 Cell Program and our T-Regulatory Cell Program and other cell therapies, including the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2014 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: Investor Contact:
LifeSci Advisors, LLC
Manager of Communications and Marketing
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.